about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Spe­cial re­port: Meet 20 ex­tra­or­di­nary women who are su­per­charg­ing bio­phar­ma R&D

4 years ago
People
Special

Pierre Beau­rang hits the ground run­ning at his 3rd start­up; Mike Grey poach­es Astel­las deal­mak­er to head pro­tein ...

4 years ago
Peer Review

ARCH-backed SciNeu­ro kicks off search for CNS au­toan­ti­bod­ies with new deal; Mer­ck + Gilead an­nounce PhII tri­al for ...

4 years ago
News Briefing

Flag­ship keeps ex-FDA com­mish Stephen Hahn busy with an­oth­er CMO gig; Daphne Koller makes key hire at in­sitro by ...

4 years ago
Peer Review

Zio­pharm finds new CEO af­ter six-month search; CFO tran­si­tion at Lon­za to take place in De­cem­ber

4 years ago
Peer Review

From bench to board­room: 20 of the most in­flu­en­tial bio­phar­ma R&D ex­ec­u­tives in drug de­vel­op­ment

4 years ago
People
R&D

As­traZeneca pro­motes on­col­o­gy ex­ec to CMO; Pfiz­er re­places re­tir­ing chief deal­mak­er as war chest ex­pands

4 years ago
Peer Review

Soros, Gates back medtech's move in­to a 'so­cial en­ter­prise'; Ag­ing an­ti-re­jec­tion drug earns fresh ap­proval

4 years ago
News Briefing

Chemo­Cen­tryx gets new PDU­FA date af­ter ma­jor amend­ment; Nim­i­um launch­es with eye on obe­si­ty

4 years ago
News Briefing

As Hutchmed awaits FDA ap­proval for su­r­u­fa­tinib, drug gets the go-ahead in Chi­na; SCO­TUS knocks back last Amarin ...

4 years ago
News Briefing

Two months af­ter ink­ing a SPAC deal, Ren­o­va­cor taps new CMO; Cure­Vac reels in a new de­vel­op­ment chief from Mer­ck KGaA

4 years ago
Peer Review

New da­ta point to how Keytru­da changed lung can­cer treat­ment; A Hous­ton biotech earns ear­ly back­ers in quest to turn ...

4 years ago
News Briefing

Lega­cies: 60 bio­phar­ma pi­o­neers over 60 who helped birth a tech rev­o­lu­tion in the mak­ing

4 years ago
People
Special

The 20(+1) un­der 40: In­side the next gen­er­a­tion of biotech lead­ers

5 years ago
Special

Diem Nguyen tapped to lead 'point of in­flec­tion' at Xalud Ther­a­peu­tics; Di­ana Es­co­lar dances her way to Avro­bio CMO

5 years ago
Peer Review

Covid-19 roundup: Hack­ers start re­leas­ing 'ma­nip­u­lat­ed' Covid-19 vac­cine docs; Ex-FDA com­mish David Kessler to ...

5 years ago
Coronavirus

News brief­ing: Chi-Med en­trusts In­ma­gene with four pre­clin­i­cal pro­grams; Xofluza nets EU ap­proval for flu pre­ven­tion

5 years ago
News Briefing

News brief­ing: 10 years lat­er, teplizum­ab gets a sec­ond shot at an FDA OK; J&J files for ami­van­tam­ab ap­proval in ...

5 years ago
News Briefing

2020’s NDA list is packed with com­mer­cial firsts — from his­toric to hap­haz­ard. Have we reached a tip­ping point?

5 years ago
Special

News brief­ing: Mer­ck buys in­to A2's T cell ther­a­py plat­form; Small Soli­genix re­ports PhI­II fail in head and neck ...

5 years ago
News Briefing

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women blaz­ing trails in bio­phar­ma R&D — Covid-19 and be­yond

5 years ago
People
Special

News brief­ing: In­tel­lia hits clin­ic with CRISPR ther­a­py; Vi­for con­tin­ues to spend, pay­ing up to $340M for DGF pro­gram

5 years ago
News Briefing

News brief­ing: Mer­ck preps FDA pitch af­ter adding more da­ta on V114; Bris­tol My­ers, Ex­elix­is get quick re­view for ...

5 years ago
News Briefing

News brief­ing: Pfiz­er on track to ear­ly '22 piv­otal read­out on he­mo­phil­ia A; Co­di­ak scales back IPO ex­pec­ta­tions

5 years ago
News Briefing
First page Previous page 10111213141516 Next page Last page
A service from the Financial Times